MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hsr2.73254

Медицинская библиотека · Health science reports · 2026

Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.

Aminu Kafayat, Amzat Jimoh, Nwebo Rita Amarachi, Nnannah Precious Chika, Ezeagu Chiamaka Norah, Edukugho Aboyowa Arayuwa, Omobowale Olubukola, Shehu Abba, Jayasinghe Yovanthi Anurangi, Amzat Ganiyat, Kanmodi Kehinde Kazeem

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Human papillomavirus (HPV) vaccination is a critical intervention for cervical cancer prevention in Africa; however, program uptake and scale-up remain limited due to financing constraints. This scoping review mapped existing evidence on HPV vaccine financing in Africa, identifying prevailing funding mechanisms, cost estimates, delivery strategies, and challenges and opportunities for sustainable financing.

METHODS

Guided by the Arksey and O'Malley framework and PRISMA-ScR guidelines, we systematically searched nine electronic databases for peer-reviewed studies. Retrieved records were deduplicated and screened against eligibility criteria. Eligible studies underwent data extraction, followed by collation, summarization, and thematic synthesis. All costs were standardized to United States (US) Dollars and further adjusted to a common reference year (2025US) using the US Consumer Price Index (CPI-U) to enable comparison across study years.

RESULTS

Twenty-seven peer-reviewed studies were included. The review found heavy dependence on donor support, particularly from Gavi, with limited domestic co-financing across most countries. Per-dose costs ranged from US$0.27-US$19.76 (financial) and US$1.31-US$45.00 (economic) as reported, or US$0.32-US$26.50 and US$1.63-US$60.36 after adjustment to 2025 US; per fully immunized girl, costs ranged from US$6.68-US$40.03 and US$17.31-US$91.19 as reported, or US$8.31-US$53.69 and US$21.53-US$122.31 adjusted. Primary cost drivers included service delivery, personnel, and outreach to out-of-school girls. School-based delivery was more cost-effective in several contexts, and the single-dose schedule consistently showed lower cost with comparable efficacy, enhancing cost-effectiveness and reducing programmatic burden. Willingness to pay exists among private individuals, but out-of-pocket models remain inequitable.

CONCLUSION

Donor funds, mainly Gavi, still drive HPV vaccination in most of Africa. The single-dose schedule cuts costs and logistics while remaining effective. For equitable, sustainable access, African countries must prioritize cost-effective vaccines, boost domestic funding, strengthen health systems, and adopt models that lessen reliance on external support.

Для цитирования: Aminu Kafayat, Amzat Jimoh, Nwebo Rita Amarachi, Nnannah Precious Chika, Ezeagu Chiamaka Norah, Edukugho Aboyowa Arayuwa, Omobowale Olubukola, Shehu Abba, Jayasinghe Yovanthi Anurangi, Amzat Ganiyat, Kanmodi Kehinde Kazeem. Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.. Health science reports. 2026. DOI: 10.1002/hsr2.73254.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.